Last reviewed · How we verify

Verve Medical, Inc — Portfolio Competitive Intelligence Brief

Verve Medical, Inc pipeline: 0 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Abbott · 1 shared drug class
  2. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  3. Ain Shams University · 1 shared drug class
  4. Boryung Pharmaceutical Co., Ltd · 1 shared drug class
  5. Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 shared drug class
  6. EMS · 1 shared drug class
  7. Kaohsiung Medical University Chung-Ho Memorial Hospital · 1 shared drug class
  8. Merck Sharp & Dohme LLC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Verve Medical, Inc:

Cite this brief

Drug Landscape (2026). Verve Medical, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/verve-medical-inc. Accessed 2026-05-16.

Related